Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7

T. Takahashi, K. Yamazaki, E. Oki, M. Shiozawa, K. Mitsugi, A. Makiyama, M. Nakamura, H. Ojima, Y. Kagawa, N. Matsuhashi, H. Okuda, M. Asayama, Y. Yuasa, Y. Shimada, D. Manaka, J. Watanabe, K. Oba, T. Yoshino, K. Yoshida, Y. Maehara

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7'. Together they form a unique fingerprint.

Medicine & Life Sciences